No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study
ABSTRACTTo assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ an...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2021-05, Vol.100 (21), p.e26023-e26023 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e26023 |
|---|---|
| container_issue | 21 |
| container_start_page | e26023 |
| container_title | Medicine (Baltimore) |
| container_volume | 100 |
| creator | Burlacu, Ruxandra London, Jonathan Fleury, Audrey Sené, Thomas Diallo, Abdourahmane Meyssonnier, Vanina Zeller, Valérie Galland, Joris Huscenot, Tessa Rubenstein, Emma Trouiller, Pierre Amathieu, Roland Kutter, Johannes Blondeel, David Lejour, Gabriel Mouly, Stéphane Lidove, Olivier Wladimir, Mauhin Sène, Damien |
| description | ABSTRACTTo assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P |
| doi_str_mv | 10.1097/MD.0000000000026023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8154429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2532249498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3322-c534d6923391c67c8ec4ff4e53a99ec155f5d405145e5743bd1427ba6c4448163</originalsourceid><addsrcrecordid>eNpdkctuFDEQRS0EIpPAF7Dxkk0nfna3WSBFE15SHlICbC2Pu8wY3O3Bdk80_Ep-FoeJQMQby9fn3ipVIfSKkmNKVHdycXZM_h3WEsafoAWVvG2kasVTtKiqbDrViQN0mPN3QijvmHiODrggnHWMLdDdZcSw9QNMFnB0uETrg_81j2aFSwJTRpgKBue8NXaHXUw4wxYSVBLb5EvVA745vb5plvErw35yYAsMeGOKr9b8Bl9DnkPJ2KU4YoMTlBTzplJ-C9jGqT5DqI6xUt5WD9QaZR52L9AzZ0KGlw_3Efry_t3n5cfm_OrDp-XpeWM5Z6yxkouhVYxzRW3b2R6scE6A5EYpsFRKJwdBJBUSZCf4aqCCdSvTWiFET1t-hN7uczfzaoThvoVkgt4kP5q009F4_f_P5Nf6W9zqnkohmKoBrx8CUvw5Qy569NlCCGaCOGfNZO1TKKH6ivI9ausQcgL3twwl-n6t-uJMP15rdYm96zaGOp78I8y3kPQaTCjrP7jsFGsYYZRI1pOmKpzx3-sLptQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532249498</pqid></control><display><type>article</type><title>No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study</title><source>Wolters Kluwer Open Health</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Burlacu, Ruxandra ; London, Jonathan ; Fleury, Audrey ; Sené, Thomas ; Diallo, Abdourahmane ; Meyssonnier, Vanina ; Zeller, Valérie ; Galland, Joris ; Huscenot, Tessa ; Rubenstein, Emma ; Trouiller, Pierre ; Amathieu, Roland ; Kutter, Johannes ; Blondeel, David ; Lejour, Gabriel ; Mouly, Stéphane ; Lidove, Olivier ; Wladimir, Mauhin ; Sène, Damien</creator><creatorcontrib>Burlacu, Ruxandra ; London, Jonathan ; Fleury, Audrey ; Sené, Thomas ; Diallo, Abdourahmane ; Meyssonnier, Vanina ; Zeller, Valérie ; Galland, Joris ; Huscenot, Tessa ; Rubenstein, Emma ; Trouiller, Pierre ; Amathieu, Roland ; Kutter, Johannes ; Blondeel, David ; Lejour, Gabriel ; Mouly, Stéphane ; Lidove, Olivier ; Wladimir, Mauhin ; Sène, Damien</creatorcontrib><description>ABSTRACTTo assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P < 10-3). Compared to the 43 patients alive at the end-of follow-up, patients who died were older (78 vs 64 years; P < 10-3), with 82% of them older than 72 years vs only 23% of live patients (P < 10-3). Age (OR = 1.15; 95%CI = 1.04-1.3; P = .008) and age over 72 years (OR) = 14.85; 95%CI = 2.7-80; P = .002) were independently associated with mortality. TCZ in addition to SOC for severe COVID-19 patients did not reduce mortality, subsequent need for invasive mechanical ventilation nor did it shorten the time of oxygen support, despite better control of the inflammatory response. More powerful and randomized controlled trials are warranted to determine if TCZ is effective in the management of COVID-19.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000026023</identifier><identifier>PMID: 34032722</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Observational Study</subject><ispartof>Medicine (Baltimore), 2021-05, Vol.100 (21), p.e26023-e26023</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3322-c534d6923391c67c8ec4ff4e53a99ec155f5d405145e5743bd1427ba6c4448163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154429/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154429/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Burlacu, Ruxandra</creatorcontrib><creatorcontrib>London, Jonathan</creatorcontrib><creatorcontrib>Fleury, Audrey</creatorcontrib><creatorcontrib>Sené, Thomas</creatorcontrib><creatorcontrib>Diallo, Abdourahmane</creatorcontrib><creatorcontrib>Meyssonnier, Vanina</creatorcontrib><creatorcontrib>Zeller, Valérie</creatorcontrib><creatorcontrib>Galland, Joris</creatorcontrib><creatorcontrib>Huscenot, Tessa</creatorcontrib><creatorcontrib>Rubenstein, Emma</creatorcontrib><creatorcontrib>Trouiller, Pierre</creatorcontrib><creatorcontrib>Amathieu, Roland</creatorcontrib><creatorcontrib>Kutter, Johannes</creatorcontrib><creatorcontrib>Blondeel, David</creatorcontrib><creatorcontrib>Lejour, Gabriel</creatorcontrib><creatorcontrib>Mouly, Stéphane</creatorcontrib><creatorcontrib>Lidove, Olivier</creatorcontrib><creatorcontrib>Wladimir, Mauhin</creatorcontrib><creatorcontrib>Sène, Damien</creatorcontrib><title>No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study</title><title>Medicine (Baltimore)</title><description>ABSTRACTTo assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P < 10-3). Compared to the 43 patients alive at the end-of follow-up, patients who died were older (78 vs 64 years; P < 10-3), with 82% of them older than 72 years vs only 23% of live patients (P < 10-3). Age (OR = 1.15; 95%CI = 1.04-1.3; P = .008) and age over 72 years (OR) = 14.85; 95%CI = 2.7-80; P = .002) were independently associated with mortality. TCZ in addition to SOC for severe COVID-19 patients did not reduce mortality, subsequent need for invasive mechanical ventilation nor did it shorten the time of oxygen support, despite better control of the inflammatory response. More powerful and randomized controlled trials are warranted to determine if TCZ is effective in the management of COVID-19.</description><subject>Observational Study</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkctuFDEQRS0EIpPAF7Dxkk0nfna3WSBFE15SHlICbC2Pu8wY3O3Bdk80_Ep-FoeJQMQby9fn3ipVIfSKkmNKVHdycXZM_h3WEsafoAWVvG2kasVTtKiqbDrViQN0mPN3QijvmHiODrggnHWMLdDdZcSw9QNMFnB0uETrg_81j2aFSwJTRpgKBue8NXaHXUw4wxYSVBLb5EvVA745vb5plvErw35yYAsMeGOKr9b8Bl9DnkPJ2KU4YoMTlBTzplJ-C9jGqT5DqI6xUt5WD9QaZR52L9AzZ0KGlw_3Efry_t3n5cfm_OrDp-XpeWM5Z6yxkouhVYxzRW3b2R6scE6A5EYpsFRKJwdBJBUSZCf4aqCCdSvTWiFET1t-hN7uczfzaoThvoVkgt4kP5q009F4_f_P5Nf6W9zqnkohmKoBrx8CUvw5Qy569NlCCGaCOGfNZO1TKKH6ivI9ausQcgL3twwl-n6t-uJMP15rdYm96zaGOp78I8y3kPQaTCjrP7jsFGsYYZRI1pOmKpzx3-sLptQ</recordid><startdate>20210528</startdate><enddate>20210528</enddate><creator>Burlacu, Ruxandra</creator><creator>London, Jonathan</creator><creator>Fleury, Audrey</creator><creator>Sené, Thomas</creator><creator>Diallo, Abdourahmane</creator><creator>Meyssonnier, Vanina</creator><creator>Zeller, Valérie</creator><creator>Galland, Joris</creator><creator>Huscenot, Tessa</creator><creator>Rubenstein, Emma</creator><creator>Trouiller, Pierre</creator><creator>Amathieu, Roland</creator><creator>Kutter, Johannes</creator><creator>Blondeel, David</creator><creator>Lejour, Gabriel</creator><creator>Mouly, Stéphane</creator><creator>Lidove, Olivier</creator><creator>Wladimir, Mauhin</creator><creator>Sène, Damien</creator><general>Lippincott Williams & Wilkins</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210528</creationdate><title>No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study</title><author>Burlacu, Ruxandra ; London, Jonathan ; Fleury, Audrey ; Sené, Thomas ; Diallo, Abdourahmane ; Meyssonnier, Vanina ; Zeller, Valérie ; Galland, Joris ; Huscenot, Tessa ; Rubenstein, Emma ; Trouiller, Pierre ; Amathieu, Roland ; Kutter, Johannes ; Blondeel, David ; Lejour, Gabriel ; Mouly, Stéphane ; Lidove, Olivier ; Wladimir, Mauhin ; Sène, Damien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3322-c534d6923391c67c8ec4ff4e53a99ec155f5d405145e5743bd1427ba6c4448163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Observational Study</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burlacu, Ruxandra</creatorcontrib><creatorcontrib>London, Jonathan</creatorcontrib><creatorcontrib>Fleury, Audrey</creatorcontrib><creatorcontrib>Sené, Thomas</creatorcontrib><creatorcontrib>Diallo, Abdourahmane</creatorcontrib><creatorcontrib>Meyssonnier, Vanina</creatorcontrib><creatorcontrib>Zeller, Valérie</creatorcontrib><creatorcontrib>Galland, Joris</creatorcontrib><creatorcontrib>Huscenot, Tessa</creatorcontrib><creatorcontrib>Rubenstein, Emma</creatorcontrib><creatorcontrib>Trouiller, Pierre</creatorcontrib><creatorcontrib>Amathieu, Roland</creatorcontrib><creatorcontrib>Kutter, Johannes</creatorcontrib><creatorcontrib>Blondeel, David</creatorcontrib><creatorcontrib>Lejour, Gabriel</creatorcontrib><creatorcontrib>Mouly, Stéphane</creatorcontrib><creatorcontrib>Lidove, Olivier</creatorcontrib><creatorcontrib>Wladimir, Mauhin</creatorcontrib><creatorcontrib>Sène, Damien</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burlacu, Ruxandra</au><au>London, Jonathan</au><au>Fleury, Audrey</au><au>Sené, Thomas</au><au>Diallo, Abdourahmane</au><au>Meyssonnier, Vanina</au><au>Zeller, Valérie</au><au>Galland, Joris</au><au>Huscenot, Tessa</au><au>Rubenstein, Emma</au><au>Trouiller, Pierre</au><au>Amathieu, Roland</au><au>Kutter, Johannes</au><au>Blondeel, David</au><au>Lejour, Gabriel</au><au>Mouly, Stéphane</au><au>Lidove, Olivier</au><au>Wladimir, Mauhin</au><au>Sène, Damien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study</atitle><jtitle>Medicine (Baltimore)</jtitle><date>2021-05-28</date><risdate>2021</risdate><volume>100</volume><issue>21</issue><spage>e26023</spage><epage>e26023</epage><pages>e26023-e26023</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>ABSTRACTTo assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P < 10-3). Compared to the 43 patients alive at the end-of follow-up, patients who died were older (78 vs 64 years; P < 10-3), with 82% of them older than 72 years vs only 23% of live patients (P < 10-3). Age (OR = 1.15; 95%CI = 1.04-1.3; P = .008) and age over 72 years (OR) = 14.85; 95%CI = 2.7-80; P = .002) were independently associated with mortality. TCZ in addition to SOC for severe COVID-19 patients did not reduce mortality, subsequent need for invasive mechanical ventilation nor did it shorten the time of oxygen support, despite better control of the inflammatory response. More powerful and randomized controlled trials are warranted to determine if TCZ is effective in the management of COVID-19.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>34032722</pmid><doi>10.1097/MD.0000000000026023</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2021-05, Vol.100 (21), p.e26023-e26023 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8154429 |
| source | Wolters Kluwer Open Health; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Observational Study |
| title | No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A20%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20evidence%20of%20tocilizumab%20treatment%20efficacy%20for%20severe%20to%20critical%20SARS-CoV2%20infected%20patients:%20Results%20from%20a%20retrospective%20controlled%20multicenter%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Burlacu,%20Ruxandra&rft.date=2021-05-28&rft.volume=100&rft.issue=21&rft.spage=e26023&rft.epage=e26023&rft.pages=e26023-e26023&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000026023&rft_dat=%3Cproquest_pubme%3E2532249498%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2532249498&rft_id=info:pmid/34032722&rfr_iscdi=true |